Literature DB >> 20321297

THE TREATMENT OF PNEUMOCOCCIC PNEUMONIA WITH SULFAPYRIDINE.

J C Meakins1, F R Hanson.   

Abstract

Entities:  

Year:  1939        PMID： 20321297      PMCID： PMC537092     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN： 0008-4409            Impact factor:   8.262


× No keyword cloud information.
  1 in total

1.  THE TOXICITY AND ABSORPTION OF 2-SULFANILAMIDOPYRIDINE AND ITS SOLUBLE SODIUM SALT.

Authors:  E K Marshall; A C Bratton; J T Litchfield
Journal:  Science       Date:  1938-12-23       Impact factor: 47.728
  1 in total
  6 in total

1.  Sulphapyridine and Pneumococcal Infections.

Authors:  H L Marriott
Journal:  Br Med J       Date:  1939-11-11

2.  SULFAPYRIDINE IN EXPERIMENTAL PNEUMOCOCCIC PNEUMONIA IN THE DOG.

Authors:  L A Gregg; M Hamburger; C G Loosli
Journal:  J Clin Invest       Date:  1940-01       Impact factor: 14.808

Review 3.  Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health.

Authors:  George H Talbot; John H Powers; Thomas R Fleming; Judith A Siuciak; John Bradley; Helen Boucher
Journal:  Clin Infect Dis       Date:  2012-06-28       Impact factor: 9.079

4.  Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia.

Authors:  Brad Spellberg; Roger J Lewis; Helen W Boucher; Eric P Brass
Journal:  Clin Investig (Lond)       Date:  2011-01-01

Review 5.  Issues in noninferiority trials: the evidence in community-acquired pneumonia.

Authors:  Thomas R Fleming; John H Powers
Journal:  Clin Infect Dis       Date:  2008-12-01       Impact factor: 9.079

6.  THE TREATMENT OF PNEUMOCOCCIC PNEUMONIA WITH SULFAPYRIDINE (DAGENAN).

Authors:  J M Kilgour
Journal:  Can Med Assoc J       Date:  1939-11       Impact factor: 8.262
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.